Ceretrieve Announces Groundbreaking Success in FIH Ischemic Stroke Cases

Core Insights - Ceretrieve's aspiration catheter has demonstrated the ability to remove clots and restore blood flow in a single pass, showcasing significant advancements in stroke treatment [1][2][4] Company Overview - Ceretrieve aims to transform stroke care by minimizing disability and improving post-stroke quality of life through innovative medical devices [2][6] - The company was established in 2017 in collaboration with The Trendlines Group and the Israel Innovation Authority [6] Study Results - A multicenter, single-arm study involving 20 patients showed that the Ceretrieve device achieved 100% Complete/Near-Complete Perfusion in all treated patients using the improved Gen 2 device [4] - The device achieved an 83% First Pass Complete Perfusion rate, significantly higher than the 30%-40% rate of current gold-standard devices [4][3] Device Features - The aspiration catheter is designed for seamless integration with conventional delivery systems, offering exceptional trackability and maneuverability [2][5] - The device features a giant bore tip that enhances vacuum effect while maintaining trackability, and it provides local flow restriction to reduce distal emboli [5] Clinical Impact - The first pass effect of the Ceretrieve device has been shown to improve patient outcomes, enabling complete clot ingestion even in challenging cases [5] - The advanced technology of Ceretrieve is setting a new standard in stroke care, leading to significant improvements in patient recovery rates [5]